Georgia’s 2011 Lethal-Injection Drug Purchase Raises Transparency Concerns
In 2011 Georgia bought its execution drugs from a West London supplier linked to a naturalised Iranian-British individual, prompting questions about secrecy laws that hide such procurement.
Georgia’s Department of Corrections purchased its lethal-injection mixture in 2011 from a pharmaceutical vendor that operated out of a West London driving-school premises and was run by a naturalised British citizen originally from Iran. The deal, later seized by the DEA, has revived debate over why U.S. states source execution drugs from overseas providers when domestic manufacturers have largely withdrawn. Opponents contend that secrecy laws enacted in states such as Georgia, Texas and Oklahoma shield drug suppliers from protest and boycott, effectively hiding the identities of those enabling executions.
The article links this secrecy to broader concerns about the death penalty, including the emotional toll on victims’ families, the risk of executing innocent people, and the psychological impact on execution staff. Personal anecdotes, like Miriam Thimm Kelle’s reflections on her brother’s killer, illustrate how prolonged death-penalty cases can become a form of ongoing punishment for families. The author calls for the repeal of shield laws to ensure taxpayers know how their money is used in capital punishment.
Why it matters
It reveals how secrecy around execution drug sourcing prevents public oversight of a practice that uses taxpayer funds and can affect justice outcomes.
In this story
